Application of mycoplasma hyopneumoniae antigen in prevention and treatment of porcine respiratory disease complex

A technology of Mycoplasma hyopneumoniae and Mycoplasma pneumoniae is applied in directions such as bacterial antigen components, antibacterial drugs, etc., and can solve problems such as reports of no preventive and therapeutic effects.

Inactive Publication Date: 2015-02-11
PU LIKE BIO ENG
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Most of the patents related to the Mycoplasma hyopneumoniae vaccine in the prior art relate to the preparation method or the method of use of the vaccine. For example, the patent with the publication number CN1551781A discloses a single-dose Mycoplasma hyopneumoniae vaccine, and the patent with the publication number CN101420975A discloses a vaccine against The vaccine of Mycoplasma and PRRSV, publi...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mycoplasma hyopneumoniae antigen in prevention and treatment of porcine respiratory disease complex
  • Application of mycoplasma hyopneumoniae antigen in prevention and treatment of porcine respiratory disease complex
  • Application of mycoplasma hyopneumoniae antigen in prevention and treatment of porcine respiratory disease complex

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Preparation of Mycoplasma hyopneumoniae Antigen

[0030] 1. Preparation of Mycoplasma hyopneumoniae seeds

[0031]After unsealing the freeze-dried strains, inoculate them in liquid medium at 10% (V / V) inoculum amount, culture them with shaking at 37°C for 3 to 7 days, and harvest them when the pH value drops from 7.5 to 6.8. seed. Take the first-grade seeds and inoculate them in liquid medium with 5% (V / V) inoculum amount, culture them with shaking at 37°C for 3-7 days, harvest when the pH value drops from 7.5 to 6.8, and use them as second-grade seeds after pure inspection.

[0032] The formula of the liquid medium: 300ml of beef heart extract (BD company), 360ml of double distilled water, correct the pH value to 7.4, and sterilize at 121°C for 15 minutes. Then add the following filter-sterilized ingredients: Hank's balanced salt solution (10×) 40m1, 0.25% (W / V) phenol red 10m1, horse serum 200m1, 5% (W / V) hydrolyzed milk protein 100m1, 25% (W / V) Yeast ext...

Embodiment 2

[0042] The preparation of embodiment 2 mycoplasma hyopneumoniae vaccine

[0043] The specific formulation of the vaccine is shown in Table 1.

[0044] Table 1 Specific formulation of the vaccine

[0045]

[0046] The specific configuration process is as follows:

[0047] According to the formula in Table 1, 10ml of the inactivated Mycoplasma hyopneumoniae HN0613 strain antigen solution prepared in Example 1, 80ml of sterile PBS buffer solution with a pH of 7.2, and 10ml of Gel 01 adjuvant (Sebic, France) were added to a sterile beaker in sequence. SEPPIC company), stirred at a speed of 500 rpm for 10 minutes at 37°C to obtain 100ml of vaccine.

[0048] Take 2ml as 1 portion / bottle, divide into packages, cover the bottle cap, and press the aluminum cap. The content of Mycoplasma hyopneumoniae was 2×10 8 CCU / Touquan.

[0049] In this embodiment, Mycoplasma hyopneumoniae is not limited to the HN0613 strain, and other pathogenic Mycoplasma hyopneumoniae strains (such as ot...

Embodiment 3

[0050] Embodiment 3 Therapeutic efficacy test of the vaccine of the present invention in PRDC pigs

[0051] In this experiment, 536 commercial pigs were included, and these pigs were divided into 2 groups randomly according to body weight and whether they were born in the same litter, namely, the vaccination group (276 pigs) A and the control group (260 pigs) B.

[0052] Group A: On the first day of the test (the 0th day), about 14 days old pigs were inoculated intramuscularly with the vaccine prepared in Example 2 once, the dose was 2ml / head, and the same vaccine and dose were used for the second time after an interval of 2 weeks. waived.

[0053] Group B: The control group was untreated pigs.

[0054] The experiment was terminated at the end of fattening (test week 24).

[0055] The parameters recorded

[0056] The parameters are documented as follows:

[0057] (1) Individual body weight (all animals)

[0058] (2) Dead pig rate (all animals)

[0059] (3) Clinical manif...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of a mycoplasma hyopneumoniae antigen or an immunogenic composition containing the antigen in prevention and treatment of PRDC (porcine respiratory disease complex) and diseases with PRDC relevant clinical evidence. Specifically, the application includes immunization of pigs with an immune dosage of the mycoplasma hyopneumoniae antigen or the immunogenic composition containing the mycoplasma hyopneumoniae antigen. Vaccination with vaccines containing the mycoplasma hyopneumoniae antigen on animals can significantly alleviate and reduce the severity and duration of PRDC relevant clinical evidence.

Description

technical field [0001] The invention relates to the application of a mycoplasma hyopneumoniae (Mycoplasma hyopneumoniae, Mhp) antigen or an immunogenic composition comprising the mycoplasma hyopneumoniae antigen in the prevention and treatment of porcine respiratory disease syndrome (Porcine Respiratory Disease Complex, PRDC). Background technique [0002] PRDCs are mainly found in grow-to-finish pigs (usually around 16 to 22 weeks of age). Morbidity rates range from 30%-70%, with an average mortality rate of 4%-6% (Kim et al., Veterinary J., 2003;166:251-256). There are more than a dozen clinical signs of PRDC, including prolonged and unusually severe cough and dyspnea refractory to antibiotic therapy, slow growth, reduced feed efficiency, lethargy, anorexia, and markedly increased mortality in mid to late finishers. These clinical signs are associated with a variety of different pathogens, common pathogens include porcine reproductive and respiratory syndrome virus (PRRSV...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/02A61P31/04
Inventor 张许科孙进忠田克恭
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap